BioSpace News Archive

Pharmascience is proud to announce additional great news with the launch of Pazopanib 200 MG & 400 MG generic in Bulgaria.

Brand Institute is proud to announce its work with Solasia Pharma K.K. (“Solasia”) in developing the brand name DARVIAS®.

Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced it will pursue an OTC Intranasal Medical Device Consumer regulatory pathway for AnQlar™.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Cardiac rhythm management includes implantable devices which help treat and manage arrhythmia-related diseases such as cardiac arrhythmia, bradycardia, tachycardia, and cardiac synchronization

Wilmington, Delaware, United States, Transparency Market Research Inc.: Sick sinus syndrome is a group disorder including three heart rhythm problems : sinus bradycardia, tachycardias, and bradycardia-tachycardia.

Wilmington, Delaware, United States, Transparency Market Research Inc.: The global membrane filters market was valued at US$ 28,134.4 Mn in 2016.

Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the appointment of Antoine Gravelle as General Counsel, effective July 1st, 2022.

NuGen Medical Devices Inc. is pleased to announce a five-year exclusive sales and distribution agreement with SOL-MILLENNIUM Medical Group, a global healthcare company dedicated to the design, manufacturing, and distribution of high-quality medical devices and personal protective equipment for patients and clinicians around the world.

Nanoscope Therapeutics , Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today announced the appointment of Michael Marquez as Chief Financial Officer.

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will be participating in a fireside chat at the William Blair Biotech Focus Conference.